Abstracts tagged "osteoporosis"

Abstract Number: 1874 • 2019 ACR/ARP Annual Meeting
Extensive Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results from the FRAME Clinical Trial
Erik Eriksen¹, Roland Chapurlat ², Rogely Boyce ³, Jacques Brown ⁴, Stéphane Horlait ⁵, Cesar Libanati ⁶, Yifei Shi ³, Rachel Wagman ³ and Pascale Chavassieux ², ¹Department of Clinical Endocrinology, Oslo University Hospital and Institute of Clinical Medicine Oslo University, Oslo, Norway, ²INSERM UMR 1033, Université de Lyon, Lyon, France, ³Amgen Inc., Thousand Oaks, CA, ⁴CHU de Quebec Research Centre and Laval University, Quebec, QC, Canada, ⁵Amgen Inc., Boulogne Billancourt, France, ⁶UCB Pharma, Brussels, Belgium
Background/Purpose: The bone-forming agent romosozumab (Romo) is a monoclonal antibody that binds to/inhibits sclerostin, leading to increased bone formation and decreased bone resorption. The highest…
Abstract Number: 2219 • 2019 ACR/ARP Annual Meeting
Randomized Control Study in Glucocorticoid-Induced Osteoporosis Treated with Bisphosphonate or Denosumab (GOBID)
Ikuko Tanaka¹, Mari Ushikubo ², Misako Konishi ², Yutaro Hayashi ², Satoshi Hama ³, Keisuke Izumi ², Yutaka Okano ², Shigenori Tamaki ⁴ and Hisaji Ohshima ², ¹Nagoya Rheumatology Clinic, Ngoya, Japan, ²National Tokyo Medical Center, Tokyo, Japan, ³tokyo medical center, tokyo, Japan, ⁴Nagoya Rheumatology Clinic, Nagoya, Japan
Background/Purpose: It has not been established which therapy, bisphosphonates or denosumab, is more effective for glucocorticoid-induced osteoporosis (GIO). The purpose of this study was to…
Abstract Number: 1877 • 2019 ACR/ARP Annual Meeting
Romosozumab Improves Lumbar Spine Bone Mineral Density and Bone Strength Greater Than Alendronate as Assessed by Quantitative Computed Tomography and Finite Element Analysis in the ARCH Trial
Jacques Brown¹, Arkadi Chines ², Roland Chapurlat ³, Joseph Foldes ⁴, Xavier Nogues ⁵, Roberto Civitelli ⁶, Tobias De Villiers ⁷, Fabio Massari ⁸, Cristiano A. Zerbini ⁹, Wenjing Yang ², Chris Recknor ¹⁰ and Cesar Libanati ¹¹, ¹CHU de Quebec Research Centre and Laval University, Quebec, QC, Canada, ²Amgen Inc., Thousand Oaks, CA, ³INSERM UMR 1033, Université de Lyon, Lyon, France, ⁴Hadassah Hebrew University Medical Center, Jerusalem, Israel, ⁵IMIM Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain, ⁶Washington University School of Medicine, St. Louis, MO, ⁷Stellenbosch University, Stellenbosch, South Africa, ⁸Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, ⁹Centro Paulista de Investigação Clinica, São Paulo, Brazil, ¹⁰United Osteoporosis Centers, Gainesville, GA, ¹¹UCB Pharma, Brussels, Belgium
Background/Purpose: Recent evidence suggests BMD achieved during treatment is a reliable surrogate for fracture risk reduction (Bouxsein JBMR 2019). Romosozumab (Romo) is a bone-forming agent…
Abstract Number: 2220 • 2019 ACR/ARP Annual Meeting
Abaloparatide Followed by Alendronate on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis
Nancy Lane¹, Richard Weiss ², Bruce Mitlak ³, Yamei Wang ⁴, Guillermo Valenzuela ⁵ and Chad Deal ⁶, ¹University of California at Davis Medical Center, Sacramento, CA, ²Radius Health, Inc, Waltham, ³Radius Health, Inc, Waltham, MA, ⁴Radius Health, Inc, Waltham, ⁵Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁶Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Osteoporosis (OP) and osteoarthritis (OA) are often comorbid conditions in the elderly, with prevalence of OP in patients with OA reported as high as…
Abstract Number: 1929 • 2019 ACR/ARP Annual Meeting
Identification and Validation of Transcriptional Genes Associated with Osteoporotic Vertebral Fractures by Microarray Study, in Community Elderly Women
Levi Jales Neto¹, Zofia Wicik ², Georgea Torres ¹, Liliam Takayama ¹, Neusa Lopes ¹, alexandre Pereira ¹ and Rosa Pereira ³, ¹University of Sao Paulo, Sao Paulo, Brazil, ²University of Sao Paulo, São Paulo, Brazil, ³Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil
Background/Purpose: The pathogenesis of osteoporosis, a common disease with high morbidity1, comprises genetic and environmental factors2. Recent studies demonstrated that blood samples are a source…
Abstract Number: 2221 • 2019 ACR/ARP Annual Meeting
Bone Metabolism Impairment in Heart Transplant: Results from a Prospective Cohort Study
Luis Seguro ¹, Rosa Pereira ², Luciana Seguro³, Valeria Caparbo ³, Monica Avila ¹, Sandrigo Mangini ¹, Iascara Campos ¹, Fabio Gaiotto ¹, Fabiana Marcondes-Braga ¹ and Fernando Bacal ¹, ¹Instituto do Coracao (InCor), HCFMUSP, Sao Paulo, ²Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil, ³Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo
Background/Purpose: Data on prevention of fractures after heart transplant (HTx) are controversial in the literature. Understanding the effects of HTx on bone may guide appropriate…
Abstract Number: 1971 • 2019 ACR/ARP Annual Meeting
CD39 Produced from Human Gingiva-Derived Mesenchymal Stem Cells Regulates the Balance of Osteoclasts and Osteoblasts Through Wnt / β-catenin Pathway in Osteoporosis
Wenbin Wu¹, Julie Wang ², feng huang ¹, limin Rong ¹ and Song Guo Zheng ³, ¹Sun Yat-sen University, Guangzhou, ²Ohio State University, columbus, ³Ohio State College of Medicine, Columbus, OH
Background/Purpose: Osteoporosis led to severe bone-related diseases and increased mortality and health care costs. Existing treatments failed to reduce the risk of fractures in patients,…
Abstract Number: 2222 • 2019 ACR/ARP Annual Meeting
Bone Health: An Independent Predictor of Coronary Artery Disease
Lilian Bizzocchi¹, Maria Salgado ¹, Bhavin Chokshi ¹, Navneet Kaur ¹, Oscar Mena ¹ and Michal Packman ², ¹Jacobi Medical Center, Bronx, NY, ²North Central Bronx Hospital, Bronx, NY
Background/Purpose: An association between low bone mineral density (BMD) and cardiovascular events has been shown. The calcification process observed in atherosclerosis and bone mineralization have…
Abstract Number: 2102 • 2019 ACR/ARP Annual Meeting
First-line Antiretroviral Therapy with Tenofovir Produces Deleterious Effects on Bone and an Increase in Proinflammatory Cytokines Expression After 12 Months of Treatment in Naïve HIV Patients
Francisco Conesa-Buendia¹, Patricia Atencio ¹, Alfonso Cabello ², Patricia Llamas-Granda ³, Ignacio Mahillo-Fernández ⁴, Raquel Largo ⁵, Gabriel Herrero-Beaumont ⁵, Miguel Gorgolas ¹ and Aranzazu Mediero ¹, ¹IIS-FUNDACION JIMENEZ DIAZ, Madrid, Spain, ²IIS FUNDACION JIMENEZ DIAZ, Madrid, Spain, ³IIS-FUNDACION JIMENEX DIAZ, Madrid, Spain, ⁴IIS- FUNDACION JIMENEZ DIAZ, Madrid, Spain, ⁵IIS-Fundación Jiménez Díaz, Madrid, Madrid, Spain
Background/Purpose: For almost two decades, bone alterations have been observed in the course of HIV infection, characterized by a marked decrease in bone mineral density…
Abstract Number: 2224 • 2019 ACR/ARP Annual Meeting
Parkinson’s Disease and Risk of Fractures : A Meta Analysis of Cohort Studies
marion louvois¹, stéphanie Ferrero ¹, Thomas Barnetche ², christian roux ¹ and Véronique Breuil ¹, ¹university of nice, nice, France, ²university of bordeaux, bordeaux, France
Background/Purpose: Parkinson's disease is a common neurodegenerative disorder in older adults. Parkinson's patients have an increase risk of falls. More over, previous studies have shown…
Abstract Number: 2204 • 2019 ACR/ARP Annual Meeting
Fragility Fractures in a Community Setting: Clinical Characteristics, Care Gaps, and Outcomes
Rachel Kneeland¹, Keile Wahle ¹, Ishwar Gill ¹, Yangyang Liu ² and Monika Starosta ³, ¹Department of Internal Medicine, Advocate Lutheran General Hospital, Park Ridge, IL, ²Russell Center for Research & Innovation, Advocate Lutheran General Hospital, Park Ridge, IL, ³Department of Rheumatology, Advocate Lutheran General Hospital, Park Ridge, IL
Background/Purpose: Osteoporosis-related fragility fractures contribute to significant morbidity and mortality. The risk of subsequent hip fracture is significantly increased after initial fracture, with some reports…
Abstract Number: 2225 • 2019 ACR/ARP Annual Meeting
Systematic Osteoporosis Screening in Chronic Obtructive Pulmonary Disease (Study of Correlation Between Pulmonary Functions Tests and Bone Parameters): Emphysematous Status Is Linked to Low Bone Density and Osteoporosis
Olivier Malaise¹, Cécile André ¹, Laurence Seidel ², Florence Schleich ³, Renaud Louis ³ and Michel Malaise ¹, ¹Rheumatology department, CHU and University of Liège, Liège, Belgium, ²Biostatistics department, CHU and University of Liège, Liège, Belgium, ³Pneumology department, CHU and University of Liège, Liège, Belgium
Background/Purpose: Chronic obstructive pulmonary disease (COPD) is usually considered as a risk factor for osteoporosis. However, COPD is an heterogeneous disease with different phenotypes, based…
Abstract Number: 151 • 2019 ACR/ARP Annual Meeting
Implementation of Recommendations for Prevention of Glucocorticosteroid-Induced Osteoporosis in Hospitalized Patients
Tal Gazitt¹, Muna Elias ¹, Joy Feld ¹, Idit Lavi ¹, Amir Haddad ¹, Rema Bishara-Garzuzi ¹, Muhanad Abu Elhija ¹, Adi Kibari ¹ and Devy Zisman ², ¹Carmel Hospital, Haifa, Israel, ²Carmel Hospital and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel
Background/Purpose: Glucocorticosteroid-induced osteoporosis (GIO) is the most common cause of secondary osteoporosis but is under-diagnosed and under-treated. Most professional guidelines recommend as a first step…
Abstract Number: 2206 • 2019 ACR/ARP Annual Meeting
MRI-based Textural Analysis of Trabecular Bone: A Novel Method for the Opportunistic Screening of Bone Quality
Jonathan Cheah¹, Matthew Koff ¹, Ryan Breighner ¹, Bin Lin ¹, Conor Jones ², Janice Havasy ², Mikas Grewal ¹ and Emily Stein ¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY
Background/Purpose: A major obstacle to the treatment of osteoporosis and prevention of fractures is that many at-risk patients are never screened. Dual energy x-ray absorptiometry…
Abstract Number: 2226 • 2019 ACR/ARP Annual Meeting
Factors Contributing to Fracture in Pernicious Anemia Patients Presenting with Symptomatic Subacute Vertebral Compression Fractures
Michael Lovy¹, Nir Ben-Shlomo ² and Jacob Hattenbach ³, ¹Desert Oasis Healthcare, Palm Springs, CA, ²Ben-Gurion Medical School, Beer Sheva, Israel, ³College of Osteopathic Medicine of the Pacific, Pomona
Background/Purpose: Pernicious anemia (PA) has been associated with both low spine BMD and increased fracture risk in retrospective cohort studies. The cause of these observations…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].